All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Enhertu 100mg Injection
Prescription Required
Salt Composition : Trastuzumab Deruxtecan
Manufacturer : ASTRAZENECA PHARMA INDIA LTD
Origin of Medicine : United Kingdom
1 Vial(s) Of 5ml
PAP Information : Buy 2, Get 1 Free. Contact us for latest updates.
Patient Assistance Programs
No Data
Introduction to Enhertu 100mg Injection
Enhertu 100mg Injection contains the active ingredient Trastuzumab deruxtecan, a targeted therapy used to treat specific types of breast and stomach cancers. It works by binding to HER2-positive cancer cells and delivering a cytotoxic agent that targets and kills these cells. Enhertu is specifically used for adult patients with HER2-positive metastatic breast cancer or HER2-positive gastric cancer, and it is not recommended for individuals under 18 years of age.
Before starting treatment, it is crucial to inform your doctor about any existing medical conditions, particularly lung, liver, or kidney issues, to ensure the medication is safe and appropriate for your treatment. Enhertu uses vary depending on the patient's condition and the progression of the disease, with treatment regimens tailored to individual needs.
Common side effects of Enhertu Injection are cough, trouble breathing or shortness of breath, fever, new or worsening breathing symptoms (e.g., chest tightness, wheezing), and low white blood cell count (neutropenia). Regular monitoring is essential during treatment to manage potential side effects and optimise therapeutic outcomes.
Uses of Enhertu 100mg Injection
Enhertu 100mg Injection is used in the treatment of the following:
- Treats HER2-positive breast cancer that is metastatic or unresectable for patients who have had prior anti-HER2 treatments.
- Effective for HER2-low metastatic breast cancer after prior chemotherapy.
- Treats HER2-mutated non-small cell lung cancer (NSCLC) that is metastatic or unresectable following prior treatment.
- Used for HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma after prior trastuzumab-based therapy.
- For HER2-positive (IHC 3+) metastatic solid tumours when no other satisfactory treatments are available.
Therapeutic Effects of Enhertu 100mg Injection
Enhertu 100mg Injection works in a targeted way to treat certain cancer cells. It is made up of two main parts:
1. Monoclonal Antibody: This part of the medication specifically attaches to cancer cells that have the HER2 protein on their surface. These are known as HER2-positive cancer cells, which are common in some breast and stomach cancers.
2. DXd (Drug Conjugate): This is the other active component of Enhertu 100 mg Injection. DXd is a powerful substance that can kill cancer cells.
Enhertu 100 mg Injection finds and attaches to HER2-positive cancer cells. Once attached, it delivers the DXd directly into these cancer cells. The DXd then works to kill these cells from the inside. This targeted approach helps attack the cancer cells while sparing many healthy cells in the body.
Interaction of Enhertu 100mg Injection with other drugs
Inform your physician about all the prescribed medicine, over-the-counter medications, nutritional or vitamin supplements, and herbal supplements you have taken before. Certain medications may interact with Enhertu 100mg Injection and can cause undesirable side effects.
More Information about Enhertu 100mg Injection
- Store in the refrigeratorat refrigerator between 2°C to 8°C.
- Do not freeze.
- It should be kept away from children and pets.
How to consume Enhertu 100mg Injection
Enhertu 100mg Injection is administered through an intravenous (IV) infusion by a healthcare provider every three weeks. Before each treatment, you may receive medication to prevent nausea and vomiting. If you have an infusion-related reaction, the infusion may be slowed, paused, or permanently stopped for severe reactions. If you miss a dose, it's important to contact your healthcare provider immediately to reschedule. The number of treatments will depend on your healthcare provider's assessment.
Safety Advices for Enhertu 100mg Injection
Pregnancy
Enhertu 100mg Injection, when taken during pregnancy, can cause neonatal complications. Hence, it is not recommended to take this medication if you are pregnant, planning for pregnancy or think you may become pregnant.
Breast Feeding
Enhertu 100mg Injection in nursing mothers has not been studied, and whether it is excreted in breast milk is unknown. Hence, it is not recommended to take this medication in breastfeeding mothers.
Lungs
If you have a history of lung disease, you may be at a higher risk of developing interstitial lung disease when using Enhertu 100mg Injection. Therefore, informing your doctor about any lung issues you have before beginning treatment with this medication is important.
Liver
Before beginning treatment with Enhertu 100mg Injection, it is important to let your doctor know if you suffer from liver impairment, as this may necessitate an adjustment in dosage depending on the severity of your liver condition.
Alcohol
Enhertu 100mg Injection is not known to interact with alcohol. However, both Enhertu 100 mg Injection and alcohol can have similar side effects, such as headaches and nausea. Be vigilant about these side effects and contact your doctor for more advice.
Driving
Enhertu 100mg Injection does not impair your ability to drive or operate machinery. However, be cautious if you feel dizzy, tired, or have a headache. Contact your doctor for more advice.
Side Effects of Enhertu 100mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.
Serious:
- Severe allergic reactions (rashes, itching, difficulty in breathing, fever)
Common:
- Nausea (feeling sick), vomiting
- Tiredness
- Decreased appetite
- Blood tests showing decreased red or white blood cells or platelets
- Hair loss
- Diarrhoea
- Constipation
- Blood tests showing increased levels of the liver enzymes such as transaminases
- Pain in muscles and bones
- Weight loss
- Fever
- Abdominal (belly) pain
- Infections of the nose and throat, including flu-like symptoms
- Headache
- Blisters in or around your mouth
- Cough
- Blood tests showing low blood potassium levels
- Indigestion
- Breathing difficulties
- Swelling of ankles and feet
- Nosebleed
- Altered/bad taste in the mouth
- Infection of the lungs
Word of Advice
If you are taking Enhertu 100mg Injection, it is crucial to regularly monitor your lung and liver functions with your doctor due to potential side effects. Both women and men should use effective contraception during treatment. Women should continue using birth control for at least seven months after the final dose of Enhertu 100mg Injection, while men should do so for four months after completing treatment to avoid risks to their partners who may become pregnant. It's essential to consult with your doctor about the best contraceptive methods and inform them before you decide to stop using contraception. Additionally, male patients should be aware that Enhertu 100mg Injection may impact fertility, so it is advisable to avoid fathering a child for four months after treatment and discuss sperm preservation options with your doctor before starting the medication.
FAQs
Q 1. What is enhertu used for?
Enhertu treats HER2-positive metastatic or unresectable breast cancer after prior anti-HER2 treatments. It is effective for HER2-low metastatic breast cancer, HER2-mutated metastatic non-small cell lung cancer (NSCLC), and HER2-positive gastric or gastroesophageal junction adenocarcinoma. It is also used for HER2-positive metastatic solid tumours when other treatments are unavailable.
Q 2. Will Enhertu 100mg Injection affect my fertility?
Enhertu 100mg Injection may have an impact on fertility. If you are planning to have children in the future, it's crucial to discuss this with your healthcare provider before starting treatment. They may suggest fertility preservation options and provide guidance tailored to your personal and family plans.
Q 3. Are there any foods to avoid while undergoing treatment with Enhertu 100mg Injection?
While on Enhertu 100mg Injection, managing nausea and vomiting is important, and your oncology care team can provide medications to help with these symptoms. Additionally, making changes to your diet can be beneficial. It's advisable to avoid foods that could aggravate these symptoms, such as heavy, greasy, or fatty foods and spicy or acidic items like lemons, tomatoes, and oranges.
Q 4. How long does adjuvant therapy with Enhertu 100mg Injection typically last for HER2-positive early breast cancer?
Based on the findings from four major studies, the standard treatment for patients with HER2-positive early breast cancer involves taking adjuvant Enhertu 100mg Injection for one year alongside chemotherapy. This approach has become the established method of care following these significant trials.
Q 5. What is the success rate of Enhertu 100mg Injection in treating breast cancer?
The success of Enhertu 100mg Injection in treating breast cancer is significant. Clinical studies have shown that the five-year invasive breast cancer-free survival rate is 97.4% among patients treated with trastuzumab.
Q 6. Can I continue my regular activities while undergoing treatment with Enhertu 100mg Injection?
Most patients can maintain their normal activities while on Enhertu 100mg Injection. However, you should monitor how you feel closely. Side effects like fatigue, nausea, or other symptoms might necessitate adjustments to your daily routine. Always consult your healthcare provider for personalized advice based on your situation.
Q 7. What is the enhertu price for 100mg injection?
The Enhertu 100 mg price typically ranges between ₹156,000 to ₹173,212, but it may vary depending on the location, healthcare provider, and specific patient needs.
Q 8. What is the Enhertu annual price?
The Enhertu price per month typically ranges between ₹156,000 to ₹173,212. Based on this, the Enhertu annual cost will be between ₹1,872,000 to ₹2,078,544. The exact price may vary depending on the patient's treatment plan and location.
Fact Box of Enhertu 100mg Injection
Molecule name: Trastuzumab deruxtecan | Therapeutic class: Chemotherapy Drugs/ Anticancer drugs |
Pharmacological Class: HER2 inhibitors
| Indications: 1. Treats HER2-positive breast cancer that is metastatic or unresectable for patients who have had prior anti-HER2 treatments. 2. Effective for HER2-low metastatic breast cancer after prior chemotherapy. 3. Treats HER2-mutated non-small cell lung cancer (NSCLC) that is metastatic or unresectable following prior treatment. 4. Used for HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma after prior trastuzumab-based therapy. 5. For HER2-positive (IHC 3+) metastatic solid tumours when no other satisfactory treatments are available. |
References
- Daiichi Sankyo UK Ltd, Electronic Medical Compendium (EMC),[Revised on July 2023][Accessed on Jan 2024] https://www.medicines.org.uk/emc/files/pil.12135.pdf
- Daiichi Sankyo, Inc, Food and Drug Safety Administration (FDA), [Revised on Jan 2021] [Accessed on Jan 2024] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf
- KD Tripathi, Essentials of Medical Pharmacology, Chemotherapy For Neoplastic Diseases, 7th edition, 2013, 930.
- Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Pharmacotherapy for Neoplastic Diseases, 12th edition, 2011, 1206.
- https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu_Med&inline=true
- https://www.enhertu.com/
Disclaimer
MrMed's primary intention is to ensure that its consumers get information that experts, accurate and trustworthy, review. The information and contents of this website are for informational purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Please seek your doctor's advice and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
